Abstract Details

Title A Real-World, Observational Study of Erenumab for Migraine Prevention in Canadian Patients With Prior Prophylactic Treatment Failure

Topic Headache

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 15-002

Background Erenumab previously demonstrated efficacy for migraine prevention in randomized controlled trials in patients who failed up to four categories of prophylactic migraine therapies. The “Migraine prevention with AimoviG: Informative Canadian real world study” (MAGIC) was designed to assess the real-world effectiveness, safety, and usage of erenumab in patients who have failed two to six categories of prophylactic migraine therapies.

Objective To assess the real-world effectiveness, safety, and usage of erenumab in Canadian migraine patients who previously failed two to six categories of prophylactic migraine therapies.

Design/Methods

MAGIC is a prospective, open-label, non-interventional, observational study conducted in Canadian patients with chronic and episodic migraine (CM; EM) who previously failed two to six categories of prophylactic migraine therapies. Participants were treated with 70mg or 140mg erenumab monthly based on their physician’s assessment. Migraine attacks were assessed using an electronic diary and migraine-related patient reported outcome (PRO) questionnaires. The primary outcome was the proportion of participants achieving a ≥50% reduction in monthly migraine days (MMD) after 12 weeks of treatment.

Results

Among the 95 participants who initiated erenumab, 89 (93.7%) received 140mg erenumab. Overall, treatment was safe and well tolerated. At Week 12, 32/95 (33.7%) participants experienced ≥50% reduction in MMD. At Week 24, 30/86 (34.9%) participants achieved ≥50% reduction in MMD. Through PROs, 65.3% and 52.3% of participants reported improvement in their condition at Weeks 12 and 24, respectively. Physicians reported improvement in the condition of 82.1% and 77.9% of participants at Weeks 12 and 24, respectively.

Conclusions One third of real-world migraine patients who previously failed two to six prophylactic migraine treatment categories achieved ≥50% MMD reduction after three months of erenumab treatment. MAGIC provides real-world evidence of erenumab effectiveness, safety, and usage for migraine prevention in adult Canadian patients with multiple prior prophylactic treatment failures.

Authors/Disclosures
Driss Rochdi, PhD (Novartis) PRESENTER	Mr. Rochdi has received personal compensation for serving as an employee of Novartis.
Werner J. Becker, MD (Foothills Hospital)	Dr. Becker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AbbVie. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Becker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Becker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for McKesson. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for University of Calgary.
Sian D. Spacey, MD, MBBS (Dr. Sian Spacey Inc)	Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for abbvie. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartits. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for lilly. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for abbvie. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for lilly. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for lundbeck. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for abbvie. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Dr. Spacey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for lilly.
Elizabeth Leroux, MD (Centre Medical Brunswick)	Dr. Leroux has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Leroux has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Innovation Canada. Dr. Leroux has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Leroux has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Leroux has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie /Allergan. Dr. Leroux has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lin Pharmaceutical. Dr. Leroux has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Paladin. Dr. Leroux has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Leroux has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Leroux has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan/Abbvie. Dr. Leroux has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Leroux has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. Leroux has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Dr. Leroux has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Leroux has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pfizer.
Rose A. Giammarco, MD	Dr. Giammarco has nothing to disclose.
Christine L. Lay, MD, FRCP (Women's College Hospital)	Dr. Lay has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Dr. Lay has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie. The institution of Dr. Lay has received research support from Teva. The institution of Dr. Lay has received research support from Lundbeck.
Jonathan P. Gladstone, MD	Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lily. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lily. Dr. Gladstone has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aralez. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Gladstone has received publishing royalties from a publication relating to health care.
Suzanne N. Christie, MD (Nepean Medical Centre)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Natacha Bastien	Natacha Bastien has received personal compensation for serving as an employee of Novartis Canada Pharma.